HIPRA leads the PIVAX project, a research initiative that aims to develop a new vaccine against infectious diseases in pigs, in order to provide new prevention and control tools to the animal health industry.

An R&D initiative to promote innovation in animal health through public-private collaboration

The project involves the participation of Leitat, a technological organization specialized in creating and transferring sustainable social, environmental, economic and industrial value, through research and technological innovation. HIPRA and Leitat will combine their expertise and knowledge to address the challenge from a highly innovative perspective, which allows progress in the effectiveness and safety of products aimed at preventing infectious diseases in pigs. 

Throughout the execution of the project, structured in four technical work packages, HIPRA and Leitat will jointly carry out the vaccine research and development process, using advanced scientific approaches. This comprehensive approach will allow to generate high value scientific knowledge and strengthen complementarity between the two organizations, consolidating HIPRA's commitment to innovation and applied research in animal health. 

The PIVAX project has a total budget of 889,650.29€, of which 409,095.95€ come from the Public-Private Partnership Projects 2021 (CPP2021) funding framework.

HIPRA’s leadership in the PIVAX project strengthens its role as a reference company in the research and development of cutting-edge vaccines and reaffirms its commitment to collaborative innovation and applied research as key pillars to offer differential solutions in the field of global health.

Project CPP2021-008589 funded by: